Increasing pressure from patients, insurers and Government to reduce the expenditure and the expiration of patents of a number of blockbuster biopharmaceutical drugs; has created a large number of opportunities for biosimilar products; imparting challenges for innovative drug manufacturers. Currently the biosimilar market is highly fragmented and huge opportunities available in the market, are attractive new players. Biocon, Dr. Reddy’s lab, Intas, LG Life Sciences, Ranbaxy, Reliance LifeSciences, Sandoz, Teva, and Wockhardt, are the major players in Global biosimilar market. Favorable regulatory developments in the biosimilar sector are expected to increase the market share, profit margins and reduce the medical expenditure, in turn from an important developing pharmaceutical market. The global biosimilar market is expected to be worth $19.4 billion by 2014, growing at an expected CAGR of 89.1% from 2009 to 2014. Biosimilar market is getting boost from increasing user acceptance and emerging Indian and Chinese markets. The major challenge for the biosimilar market is the risk involved with the high investment and possible failure of the drug during development stages. However, opportunities for biosimilar market is immense, as biologics worth $25 billion are going to be off patent by 2016 and an anticipated approval pathway in U.S. will open up potentially largest market.

The briefing on the Global Biosimilar Market (2009-2014) will benefit the Active pharmaceutical ingredients (APIs) manufacturers, contract research organizations, biosimilar drug manufacturers, medical/pharma associations, research labs, healthcare service providers, regulatory authorities, and technology providers.

“We can expect to see a significant growth opportunity for early movers as the demand of biosimilar products is estimated to increase tremendously, triggered by key patent expiry of biopharmaceutical drugs, and new product launches at the reasonable prices. Moreover, the Americas is expected to dominate the Global biosimilar market in 2014 with 36% of global biosimilar revenue, following by estimated opening of U.S. market in 2010” notes MarketsandMarkets. “High research cost and a significant time gap between development and commercialization is proving out to be the major challenge for the companies joining this industry.”

MarketsandMarkets, a research and consulting firm now onto publishing, is producing high level strategically analyzed 250 page reports about 120 a year. Worldwide, market research reports are primarily sold for numbers, market segmentation and competitive landscape, within the business leaders. MarketsandMarkets reports are equipped with more than 100+ market data summary tables, in-depth segmentation up to level 5 for each of the products, services, applications, technologies, ingredients and stakeholders categories. Our reports of about 250 pages analyze about 200 patents, over 50 companies and micro markets which are collectively exhaustive but mutually exclusive. The analyst working with MarketsandMarkets come from the renowned publishers and market research firms globally adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a database of hundred thousand of key industry participants and draw on our relationship with more than 900 market research companies globally. We, at MarketsandMarkets, are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our report, please visit our website (www.marketsandmarkets.com)

Note: An email containing the Login Details and Time of the Analyst Briefing will be sent to you soon after your successful registration.